The Effect of Injectable Platelet-Rich Fibrin in Peri-implant Soft Tissue
Evaluation of the Effect of Injectable Platelet-Rich Fibrin on Peri-Implant Soft Tissue Phenotype
Kutahya Health Sciences University
80 participants
Dec 15, 2022
INTERVENTIONAL
Conditions
Summary
An inadequate amount of peri-implant soft tissue results in more plaque accumulation around the implants, peri-implant mucositis, marginal bone loss, mucosal recession, and/or attachment loss. In the literature, there are studies evaluating the application of injectable platelet-rich fibrin to the gingiva and oral mucosa around teeth, but injectable platelet-rich fibrin application around implants has not been encountered. This study aimed to evaluate the effect of subgingival and submucosal application of injectable platelet-rich fibrin on peri-implant soft tissue phenotype in patients with inadequate peri-implant soft tissue phenotype.The study will include 80 systemically healthy and non-smoking patients/implants older than 18 years of age with insufficient peri-implant keratinized mucosa width and mucosal thickness who applied to Kütahya University of Health Sciences, Faculty of Dentistry, Department of Periodontology. There are two study groups according to peri-implant mucosa phenotype: Thin phenotype and thick phenotype. All patients will undergo the same procedure of injectable platelet-rich fibrin application
Eligibility
Inclusion Criteria5
- be over 18 years old
- The patient does not have any systemic disease
- Patients who do not smoke or who smoke less than 10 cigarettes
- Peri-implant keratinized mucosa width less than 2 mm
- Peri-implant mucosal thickness less than 2 mm
Exclusion Criteria7
- Being out of the defined age group
- Any systematic contraindication for periodontal surgery
- Patients who smoke more than 10 cigarettes per day
- Patients with adequate peri-implant keratinized mucosa width and mucosal thickness
- Pregnancy
- Patients taking medication that suppresses the immune system or impairs healing
- Patients taking medication that impairs the bleeding condition
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The injectable platelet rich fibrin will be integrated into the tissue by subgingival and submucosal application to the keratinized gingiva of the implant sites with insufficient peri-implant soft tissue phenotype. Then, the prepared injectable platelet rich fibrin will be injected into the mucogingival junction apical to the keratinized gingival site. This procedure will be repeated 3 times in total, 1 time in 30 days for 3 months.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06753396